PL1759702T3 - Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem - Google Patents

Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem

Info

Publication number
PL1759702T3
PL1759702T3 PL04748557T PL04748557T PL1759702T3 PL 1759702 T3 PL1759702 T3 PL 1759702T3 PL 04748557 T PL04748557 T PL 04748557T PL 04748557 T PL04748557 T PL 04748557T PL 1759702 T3 PL1759702 T3 PL 1759702T3
Authority
PL
Poland
Prior art keywords
solution
preparing
produced
latanoprost ophthalmic
ophthalmic solution
Prior art date
Application number
PL04748557T
Other languages
English (en)
Inventor
Bayardo Arturo Jimenez
Montano José Rubén Tornero
Sanchez María Isabel Lopez
Olmos Enrique Cruz
Original Assignee
Bayardo Arturo Jimenez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35450648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1759702(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayardo Arturo Jimenez filed Critical Bayardo Arturo Jimenez
Publication of PL1759702T3 publication Critical patent/PL1759702T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL04748557T 2004-05-26 2004-05-26 Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem PL1759702T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04748557A EP1759702B1 (en) 2004-05-26 2004-05-26 Method of preparing a latanoprost ophthalmic solution and solution thus produced
PCT/MX2004/000034 WO2005115401A1 (es) 2004-05-26 2004-05-26 Un método para preparar una solución oftálmica de latanoprost y solución resultante

Publications (1)

Publication Number Publication Date
PL1759702T3 true PL1759702T3 (pl) 2009-06-30

Family

ID=35450648

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04748557T PL1759702T3 (pl) 2004-05-26 2004-05-26 Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem

Country Status (12)

Country Link
US (4) US8293789B2 (pl)
EP (1) EP1759702B1 (pl)
AR (1) AR049113A1 (pl)
AT (1) ATE419854T1 (pl)
BR (1) BRPI0418866A (pl)
DE (1) DE602004018990D1 (pl)
DK (1) DK1759702T3 (pl)
ES (1) ES2320770T3 (pl)
PL (1) PL1759702T3 (pl)
PT (1) PT1759702E (pl)
SI (1) SI1759702T1 (pl)
WO (1) WO2005115401A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609634B2 (en) * 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
EP2167546A1 (en) * 2007-07-11 2010-03-31 Ophthalmopharma AG Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US9481856B2 (en) * 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
US10463677B2 (en) * 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
EP3920988A4 (en) * 2019-02-06 2022-11-02 Tearclear Corp. SYSTEMS AND METHODS FOR REMOVAL OF PRESERVATIVES FROM OPHTHALMIC FORMULATIONS INCLUDING COMPLEXING AGENTS
US11253518B2 (en) * 2019-08-07 2022-02-22 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss
EP4167965A1 (en) * 2020-06-21 2023-04-26 i.com Medical GmbH Use of high molecular weight hyaluronic acid as ocular transporting vehicle

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
ATE289817T1 (de) 1998-12-25 2005-03-15 Sucampo Ag Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
JP2003531824A (ja) 2000-02-01 2003-10-28 ケイマン ケミカル カムパニー，インク． フルプロステノールおよび関連プロスタグランジンＦ２α類似体の内部１，１５−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US20030018079A1 (en) * 2000-11-13 2003-01-23 Richardson Helene Treatment

Also Published As

Publication number Publication date
US20110098355A1 (en) 2011-04-28
US20110105605A1 (en) 2011-05-05
US8293789B2 (en) 2012-10-23
DK1759702T3 (da) 2009-04-20
DE602004018990D1 (de) 2009-02-26
SI1759702T1 (sl) 2009-06-30
PT1759702E (pt) 2009-04-13
EP1759702A1 (en) 2007-03-07
ES2320770T3 (es) 2009-05-28
WO2005115401A1 (es) 2005-12-08
US20080021101A1 (en) 2008-01-24
BRPI0418866A (pt) 2007-11-20
ATE419854T1 (de) 2009-01-15
US20110098354A1 (en) 2011-04-28
AR049113A1 (es) 2006-06-28
EP1759702B1 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
PT1759702E (pt) Método de preparação de uma solução oftálmica de latanoprost e a solução assim produzida
IL179700A0 (en) Ocular implant and methods for making and using same
EP1748077A4 (en) PROCESS FOR PROTEIN PRODUCTION
EP1752240B8 (en) Three-dimensional shape model producing method and apparatus
SG123727A1 (en) Nanofiber construct and method of preparing thereof
EP1814582A4 (en) METHOD FOR REDUCING MEDICAMENT-INDUCED SIDE EFFECTS IN A PATIENT
IL184917A0 (en) A prosthesis and method of manufacturing a prosthesis
HK1087067A1 (en) Method and molds for producing ophthalmic lenses &xa
GB0518220D0 (en) Method of preparing a hydrogel
EP1776948A4 (en) METHOD FOR PRODUCING LIPOSO-CONTAINING PREPARATION
EP1747494A4 (en) GLASSES AND ASSOCIATED MANUFACTURING METHOD
EP1764416A4 (en) PROCESS FOR THE MANUFACTURE OF THEANIN
PT1754215E (pt) Processo e sistema de exibição para estimular o pestanejar dos olhos de um utilizador por modificação subliminar de parâmetros de exibição
GB0402743D0 (en) Method of manufacturing a dental part
EP1618857A4 (en) Single-piece Intraocular lenses and methods of production therefor
GB0414772D0 (en) Ophthalmic eye preparation
GB2403908B (en) Artificial cornea
EP1634958A4 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN CARBOXYLATE
EP1692323A4 (en) PROCESS FOR PRODUCING NANOSTRUCTURE POINTS
GB0501336D0 (en) A method of producing a mould
ZA200704132B (en) Method of producing a carnitine-synthesising micro-organism
EP1721887A4 (en) OPTICALLY ACTIVE 1-ARYL-2-FLUORO-SUBSTITUTED ETHYLAMINE AND PROCESS FOR THE PRODUCTION THEREOF
GB0514455D0 (en) Method of making structural members
GB0405465D0 (en) A cup and its method of production
GB2416754B (en) A bag and a method of making a bag